09:47 AM EST, 12/12/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Thursday it has signed a licensing deal with Neopharm Israel for the exclusive rights to commercialize cholesterol medications Nexletol and Nexlizet in Israel.

Under the terms of the agreement, Esperion will grant Neopharm exclusive commercialization rights to the drugs in Israel, Gaza, and the West Bank.

In return, Esperion will receive upfront and near-term milestone payments, and will be eligible to receive tiered royalties on sales of the drugs in Israel.

Price: 2.62, Change: -0.07, Percent Change: -2.79